News Column

Recent Findings from Harvard University Provides New Insights into Drug Delivery (Bioengineered baculoviruses as new class of therapeutics using...

July 25, 2014



Recent Findings from Harvard University Provides New Insights into Drug Delivery (Bioengineered baculoviruses as new class of therapeutics using micro and nanotechnologies: Principles, prospects and challenges)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies. According to news reporting from Cambridge, Massachusetts, by NewsRx journalists, research stated, "Designing a safe and efficient gene delivery system is required for success of gene therapy trials. Although a wide variety of viral, non-viral and polymeric nanoparticle based careers have been widely studied, the current gene delivery vehicles are limited by their suboptimal, non-specific therapeutic efficacy and acute immunological reactions, leading to unwanted side effects."

The news correspondents obtained a quote from the research from Harvard University, "Recently, there has been a growing interest in insect-cell-originated baculoviruses as gene delivery vehicles for diverse biomedical applications. Specifically, the emergence of diverse types of surface functionalized and bioengineered baculoviruses is posed to edge over currently available gene delivery vehicles. This is primarily because baculoviruses are comparatively non-pathogenic and non-toxic as they cannot replicate in mammalian cells and do not invoke any cytopathic effect. Moreover, emerging advanced studies in this direction have demonstrated that hybridizing the baculovirus surface with different kinds of bioactive therapeutic molecules, cell-specific targeting moieties, protective polymeric grafts and nanomaterials can significantly improve the preclinical efficacy of baculoviruses. This review presents a comprehensive overview of the recent advancements in the field of bioengineering and biotherapeutics to engineer baculovirus hybrids for tailored gene therapy, and articulates in detail the potential and challenges of these strategies for clinical realization."

According to the news reporters, the research concluded: "In addition, the article illustrates the rapid evolvement of microfluidic devices as a high throughput platform for optimizing baculovirus production and treatment conditions."

For more information on this research see: Bioengineered baculoviruses as new class of therapeutics using micro and nanotechnologies: Principles, prospects and challenges. Advanced Drug Delivery Reviews, 2014;71():115-130. Advanced Drug Delivery Reviews can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Advanced Drug Delivery Reviews - www.elsevier.com/wps/product/cws_home/505508)

Our news journalists report that additional information may be obtained by contacting A. Paul, Harvard University, Brigham & Women's Hospital, Sch Med, Center Biomed EngnDept Med, Cambridge, MA 02139, United States. Additional authors for this research include A. Hasan, L. Rodes, M. Sangaralingam and S. Prakash (see also Drugs and Therapies).

Keywords for this news article include: Cambridge, Massachusetts, United States, Drugs and Therapies, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Drug Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters